Reddit Posts
CRMD down 60% , why and what. Analyst target at 500% upside.
Imagine being a bagholder in CRMD from the top
CRMD has a PDUFA date this month; analyst gives it 75% upside
CRMD has a PFUFA date this month; analyst gives it 75% upside
Mentions
Forgot to post the earnings, but CRMD threw down another great report. $1.25 quarterly adj. EPS on an $11 stock is nuts. Another way to look at it...$108 million in quarterly net income on an $800 million company. Insanely cheap.
Whoever shouted about CRMD, thank you, looks like a winner after those blowout earnings...Glad I bought in...
CRMD its being squees... Short float @ >20%
[https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix\_biotech\_potential\_short\_squeeze/?utm\_source=share&utm\_medium=web3x&utm\_name=web3xcss&utm\_term=1&utm\_content=share\_button](https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix_biotech_potential_short_squeeze/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button) I went into it a little bit a couple months ago and still think it could squeeze, but not from this. I've been in the stock for over 3 years and these numbers are insane and pt should be a lot more, but there was a shelf offering in June right after LDO1 was signed and an acquisition of Melinta. The dark cloud hanging over it right now is CMS TDAPA reimbursement news. CRMD has requested an extension and updated pricing for post TDAPA which will begin next summer. If they get good news, it could seriously take off. Also, real world evidence study results will be released by the end of year. If that comes back as we all hope, showing that it prevents infections at the rate it does, it could pop as well. While I do think we'll see nice movement today, I don't think the true value and squeeze will come until the CMS decision is released.
VIVK a good play this week. Huge volume on monday with no real price movement = institutional accumulation. Was expecting something yesterday but it was a pretty flat day across the board. Holding strong for now. Trimming FEMY, CRMD, and HUMA today if these good ERs fetch me some profit and I’ll load up on more VIVK if price is still stable. Got a good feeling about this one.
glad i bought yesterday CRMD, hope it will continue the growth
CRMD predictions for Wednesday?
CRMD easiest bet of my life. FWD P/E of 4 for a biotech! Buy and win with me!
For the most part I swing trade MARA and SOFI (avoiding SOFI rn tho due to recent EPS and not establishing new lower/higher resistance levels yet) I take stabs at promising penny set ups and roll any profits into more SOFI shares or AMZN/GOOG/ CRMD
Informed Insider buys at CorMedix leading up to earnings report I implore you to look into CRMD. I will not shill. #CorMedix
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
$CRMD make me so HOOOORRRRRRRNNNNNNYYYYYY
$CRMD about to pop. earnings next week and major insider buying. Profitable company with no debt and large short interest. its at 11.31 now, Questrade has its target at $19, and SWS has it a $270.
Lets pump CRMD back to ATH of $49
CorMedix is rated top biopharma-turned-tech company. #All in on CRMD.
Bullish here too. Notably, the technicals are pointing to a burst of buying interest. **Moving Average Momentum:** Very recently, CRMD's 73 Day moving average shot above its 78 moving average. In the past, when this happened, CRMD tended to climb about 2.62% the next day on average, with a high statistical confidence (p-value of 0.00388). This pattern has appeared 52 times in the past. This suggests a burst of buying interest. **Moving Average Resistance:** CRMD's 105 Day moving average is now touching its 106 moving average. This contact is flagged as a potential mean-reversion setup, often signaling short-term strength. Historically, CRMD climbed about 1.67% the next day on average, with a high statistical confidence (p-value of 0.00971), across 98 past cases. These are all from [**SiriusAI**](http://www.siriussignals.com) but worth noting!
Good morning! I've been in CRMD for over 3 years and posted about it 3 weeks ago. That post is [here](https://www.reddit.com/r/Shortsqueeze/comments/1nubni4/crmdcormedix_biotech_potential_short_squeeze/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button) . Just wanted to clarify some things about it. Yes, this is amazing news and shows sales are better than expected even a month ago when they raised guidance the first of September. Defencath utilization is better than expected for the LDO1, which is huge news too. However, the most important news for the stock in the short term is the CMS TDAPA reimbursement decision. If it comes back negative, it would prevent any squeeze whatsoever. If it comes back the way we hope, then we would probably see it. Also, potential short term catalysts (if TDAPA decision is neutral or not as good as expected) would be LDO2 sign on, Real world study results and FDA approval on Rezzayo. Keep in mind, that while the deadline for the TDAPA decision was November 1, that could be delayed due to the government shutdown. I'm not posting these things to dissuade anyone from getting in the stock, just wanting to clarify the picture. CRMD has exceeded sales since last July when they began, but the stock always gets beaten back down. Even with the news this morning, we're still sitting lower than at the beginning of October(and much less than the beginning of September even after raising guidance).
Ah, CRMD- haven't seen that ticker for like 5+ years when I was gambling on trash penny stocks. It's still trash. Run from all these unless you hate making money.
Today's Buys: NEXM, CRMD, ALMS, FRSH
Short CRMD. They're diluting by 50%
#CorMedix (CRMD) ● Debt:equity = 0.00 (no debt) ● revenue up 5,000% ● current margins = 50% ● projected margins of 85-95% ● forward PE of 7.0
Hey man nice informative post. I was also looking at opening a position on TLPH purely on the speculation of FDA approval and CRMD acquisition, however I wasnt sure whether current price is good or whether I should wait for a pull back down to about $0.70
The safest investment on the market right now is CorMedix (CRMD)
JMP Securities analyst Jason N. Butler reiterates Cormedix (NASDAQ:CRMD) with a Market Outperform and maintains $22 price target.
TLPH - Talphera, Inc \>Link [https://talphera.com/](https://talphera.com/) scroll down to view pipeline \>I'm looking forward on this and need everyone opinions on this! **January 2025** Lead candidate Niyad™ (nafamostat mesylate), FDA granted Breakthrough Device Designation in January 2025. Nafamosta (raw drug, generical chemical) widely used in Asia for decades. The distinction of Niyad would be on US first FDA FDA-approved regional anticoagulant for CRRT in ICU patients (if approved). At present in the US doctors used unapproved workarounds. FDA designation and immediate commencement of Phase 3 is probably FDA recognized the real world usage and decades of use in Asia. Hence, the risk of failure is low. **Catalyst** End of 2025, Phase 3 result positive > PMA target filling in first half of 2026 > FDA decision 2nd half of 2026. \*in between 60 days post phase 3 result, there is possibilities on CRMD looking to buy TLPH\* **Where the RISK?** Reverse split, they need to meet min bid 1.0 by December 1 2025. The price about to reach 1.0, and it must maintain it for 10 consecutive business days! [https://ir.talphera.com/static-files/1774ca90-a5c3-41b4-af85-4661c4dcff9c](https://ir.talphera.com/static-files/1774ca90-a5c3-41b4-af85-4661c4dcff9c) Upcoming Annual Meeting to vote for RS - preliminary, and date set on October 23 2025. [https://ir.talphera.com/static-files/1c6ab3cd-ee27-42b2-8b7e-a4fe04e19055](https://ir.talphera.com/static-files/1c6ab3cd-ee27-42b2-8b7e-a4fe04e19055) **August 2025** TLPH is now enrolling patient and on track for study completion by end of 2025. Main catalyst! The size of patients was FDA-approved reduction in required sample size - from 166 to 70. [https://ir.talphera.com/news-releases/news-release-details/talphera-announces-achievement-17-patient-enrollment-milestone](https://ir.talphera.com/news-releases/news-release-details/talphera-announces-achievement-17-patient-enrollment-milestone) Recent news, CRMD together with other new and existing investors made an equity investment in TLPH via private placement. This provide TLPH sufficient capital through approval of Niyad in the second half of 2026. The private placement also provided CRMD; "60 days exclusivity following the announcement of the achievement of the primary endpoint and topline clinical study results from the NEPHRO CRRT clinical study to negotiate a definitive agreement to acquire Talphera. CorMedix also has the right to nominate a representative to the Talphera Board of Directors." The current cash should be at approximately 20mil+/-. [https://ir.talphera.com/news-releases/news-release-details/talphera-announces-private-placement-financing-29-million-priced](https://ir.talphera.com/news-releases/news-release-details/talphera-announces-private-placement-financing-29-million-priced)
Some of the short positions on decent stocks is amazing. UFPT has like 20% of the float short. CRMD too. Interesting theory I heard: long short funds have been increasingly long on NVDA requiring more and more shorts to counter that position. However, the flip side is that of NVDA sells off, those funds will be forced to close those shorts which could lead to a really violent rally in small caps. IWM and oil both have near record short positions and could see similar rallies. Interesting theory, we'll see what happens with it.
CRMD: we're raising our guidance! Market: sell!
CRMD update on guidance: Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 million Revised Full Year Financial Guidance Pro forma 2025 Revenue: $325 million – $350 million Pro forma 2025 Synergized Adjusted EBITDA: $165 million – $185 million DefenCath® 2025 Revenue: $200 million – $215 million
CRMD They have a drug that reduces infection during dialysis. They also just made an acquisition that expanded their portfolio. Trading around 7x forward earnings, even if they don't land any other clients for dialysis....which they likely will.
Definitely. I tend to have a lot of low beta larger names as well. Also, a lot of thinly traded names that move some what independently of the market. That helps. I'm resigned to the fact that I might have some ugly days on the trail though. CRMD went from $16.5 down to $9 in the time I've owned it. Small caps are an adventure.
Solid trio for medical. I've been accumulating shares of CRMD. They have a drug that greatly reduces infections during dialysis. Even if they sign no new clients they're at like 9-10x forward earnings. However, there's a lot of potential new customers so that could even be low. Also adding to UFPT. They do packaging for medical devices, sort of a MEDP type play, bit for devices instead of drugs.
NBIS is a weird one....I bought it at $23, which was below the value of its assets. I figured it was a solid risk/reward at that point. It's definitely gotten expensive since then, which is why it's so big for me. My recent buys are ABL, CRMD, and NE, as well as OPRA. I'm not able to make the leap to Japanese names unfortunately. However, I'm still finding plenty of value out there.
Great acquistion and I think this is a very good purchase for $CRMD. Its certaily going to be a long term hold for me
I firmly believe that the "everything is expensive" crowd just doesn't look at enough names. OPRA: rule of 40 web browser trading at 16.5x earnings. Also pays a 5% dividend. NXT: utility solar isn't as rough as residential, and this gem is trading at 14.7x earnings. ODD: cosmetics name with 25%+ annual growth, trading at 22x EV/earnings. That's not even counting names with cheap forward earnings like CRMD (6x) or ABL (7x). Like Peter Lynch, turn over rocks.
I'm out of CRMD now. I may be wrong but hate acquisitions and think this was not a good use of capital. Such a shame, I hope they prove me wrong
CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC (“Melinta”), a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced a definitive agreement for CorMedix to acquire Melinta. The selling shareholders will receive $300 million in total consideration at closing, including $40 million of CorMedix equity, and will be eligible to receive a regulatory milestone of up to $25 million and royalties on net sales of MINOCIN® and REZZAYO™.
Where should I go balls deep into: Recursion pharmaceuticals or Tempus AI? I'm mid shaft into CRMD.
For pharma I would bet so. 🥭 explicitly said he wants meds American and be made in America. My money is on CRMD as they are in both markets under different labels.
Stealth accumulation of CRMD over the past few weeks. Earnings coming in good. Steady profit margin of 40-70% with increased Healthcare provider network. Earnings in 2 weeks. Forward PE of 7. Short interest at 11-20% This seems too easy. Check their SEC filings for their numbers and FDA for their regulatory exclusivity. The volume on bullish patterns inconsistent with regular volume. I put 6 bands down at 11.40. Do your own research, but this is definitely investment advice. Invest.
Stealth accumulation of CRMD over the past few weeks. Earnings coming in good. Steady profit margin of 40-70% with increased Healthcare provider network. Earnings in 2 weeks. Forward PE of 7. Short interest at 11-20% They mods here won't let me post the DD for some reason but this seems too easy. Check their SEC filings for their numbers and FDA for their regulatory exclusivity. The volume on bullish patterns inconsistent with regular volume. I put 6 bands down at 11.40. Do your own research
I've been buying ABL and CRMD. ABL was beaten down by a short report. The company is very complex, but is probably very oversold. CRMD is cheap, and if they execute well, extremely cheap, based on forward earnings. Risky though as they have a single product they sell. If that demand dried up, it gets expensive in a hurry. There's a lot more deals in the small cap space, imo, but it is also more risky.
Short squeeze on CRMD. #buy buy buy buy
#CRMD I tried to tell you all but the ghey mods wouldn't allow my DD
How do you get to post this shitty as nonsense, but mods won't let me post actual DD on #CRMD
How do you get to post this shitty as nonsense, but mods won't let me post actual DD on #CRMD
Let's definitely NOT prump&drump CRMD
Mods please answer me. I'm just trying to post DD on CRMD. This is definitely financial advice. Why am I banned?
Dca on CRMD was the best financial decision I've ever made
This is actually very good for Cormedix #CRMD
Intel, MP, MU, SBSW, CRMD, AMPX. Intel is by far the largest though.
$CRMD, has great underlying market, didn't understand the rug pull?
ABL got hit by a short report, which seems to be a nothing burger (management is acting accordingly). BNED is transitioning to a high margin recurring revenue business, but is not yet priced as such, in my opinion. CRMD is trading around 7-8x their guided earnings for next year, but growing at massive rates. CHE sold off yesterday on a Medicare issue, but it's a great company. NXT gets sold off as a residential solar play, but they do utility solar which is less sensitive. IBP is a builder and will benefit from lower rates. REAX is real estate, same rate play.
Been buying: BNED, ABL, and CRMD lately. High on the watchlist: CHE, REAX, NXT, IBP
CorMedix (CRMD) shares were over 11% lower premarket Friday after the company said it has priced an underwritten public offering of about 6.6 million shares for expected gross proceeds of about $85 million. The offering is expected to close on or about June 30, the company said. CorMedix said it granted underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the offering. The biopharmaceutical company said it intends to use the net proceeds for general corporate purposes that may include working capital, expenses tied to developing product candidates, and potential acquisitions, joint ventures or collaborations.
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $15 to $20.
Almost every comment here about GOOG, TSLA and politics... meanwhile names brought up last week like ZETA, CRMD, and others up 20% or more today.
CorMedix (CRMD) said Monday that its large dialysis organization customer has begun ordering and will start implementing DefenCath in H2 2025, targeting at least 50% more patients than previously planned. The company said it had amended its agreement with the organization to reflect this broader rollout, which is expected to contribute modestly to June revenue and drive stronger growth in the second half of the year. Due to the expanded implementation, CorMedix has raised its Q2 net sales guidance to a range of $35 million to $40 million from $31 million.
After reading Substack on CRMD, added the position
Anyone look into CRMD? I've been reading a great breakdown on Substack but wasn't sure if anyone has looked into the name. Huge growth prospects if it executes.
Sold off my big losses, jumped on PLTR heavy when when it was at 40, and rode it to 115, and my only remaining long came through, CRMD, at right about the same time, and still looking for that to double again. Not really at strategy change, just got the timing right, and had patience. Dont really do options much. See to many bad things.
Interesting! My strategy for my taxable is a bit more forward looking. I'm taking big swings at what I anticipate will be growing markets in the future (EVTOL, space, medtech, water). There's plenty of hard times and patience involved, but if enough hit, it shakes out in my favor. BWAY is my biggest gainer (though I wasn't heavily invested there), along with RKLB, SOFI, SHOP, and PLTR (sold off most of the last two at peak). There's plenty more grounded stuff as well, but those are just to balance things out. I'll take a look at CRMD. I'm very intrigued by biotech, but my picks haven't panned out so far.
It's definitely possible. I'm beating it for going on 3.5 years now. And this year blowing it out of the water. Up almost 15% YTD at close yesterday. Ive usually got about 3 deep value/hunches. Usually small caps and not tech sector. CROX is my #1 gainer this year followed by CRMD. EWBC is another top 5 pos that I think is special. But I'm a nerd and have read so much on my top 5 or 6 positions.
About 30% cash since like September. As of today about 4% in SH inverse etf. Down a couple% at today's close. We go higher than here I'll think about 2x or 3x inverse funds. I do have good positions though. TLT long term bonds started the last week or two. About flat in that as of now. About 3% position. 12% in CROX. Very, very low PE for a low growth stock with amazing margins. They have tons of cash flow and have stock buyback authorized at 20% of the entire market cap. They'll probably announce more at earnings this week. 10% in CRMD. this is my focus this year. Small cap biotech involved in anti bacterial catheter solutions. Ridiculously cheap stock for what is a high growth bio stock. The product just isn't sexy. Might be a slow grower that can hit 45/share in the next couple years unless they get a BO. 8% in EWBC. Very conservative but high margin regional bank based on West Coast. Asian American focused but has been untouched by China tariffs. Leadership team had been in the US for decades. The rest is only notable for healthcare and European healthcare stocks at that. And oil stocks. Oil is just very low right now I had a big gold position but that's mostly sold now and gold maybe topping. I'm up almost 9% YTD
CRMD. had a bad ER where they pushed back a new big customer but eventually...some day...the thing is worth at least 25/share and maybe 40. Small cap biotech. Already has positive earnings they're just having sales issues.
I have a leveraged portfolio I am very interested in but it might be stupid I put Leaps but it can be leveraged single stock ETFs, I'm not too sure about the pros and cons. I think I will aim for around 2x leverage **General:** 80% Leveraged stock (60% well established companies, 20% slightly speculative) 10% fake internet money 10% Precious Metals **Specific:** 10% ASML Leaps 10% MSFT Leaps 10% GOOGL Leaps 10% NVDA Leaps 10% QCOM Leaps 10% NVO Leaps 10% CRMD Leaps 10% HOOD Leaps 5% (removed, bot) 5% (removed, bot) 5% Platinum 5% Gold No way I would enter this portfolio right now though, looks like a bear market is starting, so I would start DCAing into it when I feel the time is right, probably not anytime in the next 6 months
It's well known that low volume options have massive bid/ask spreads...I love CRMD btw, crazy how much they dumped this week
\>> I feel the need to post on arguably the best sub for some investment advice in these mild times. I loved that closing line. I feel compelled to add something so I'm gonna do two: CRMD, VTIP.
I’ve been riding ADTN from its low of $5.6 last year up to its current price. Hoping to start trimming around the $15-$16 price range, as this is a cyclical business. I noticed on their balance sheet that they were starting to generate profits again and I was able to catch the beginning of this cycle early. It’s been one of my better performing stocks in my portfolio this year. Another example was CRMD, they make catheters used in nearly every hospital in America and they’re valued at less than a billion. It has also been a top performer for me.
CRMD... Thank me later
That’s fair, if I get assigned I’ll do some covered calls. My intention was to collected premiums and invest the proceeds into CRMD shares.
Could do a CKPT play on whether they will get approval or not in December or just sit on CRMD long term shares.
I’m assuming they provided forward guidance on q3? Stocks usually go down if the forward guidance isn’t super bullish. I’m a big investor of CRMD and even though we had a very bullish quarter, they couldn’t provide a forward guidance due to contracts being ramped up and they also did an ATM on the same day.
I'm in CRMD and ADMA. Both have room to run still and are good acquisition targets, IMO.
CRMD I’m an idiot tho. Hoping to see $17 next year but they’re FDA approved and starting to make some big deals on the supply side. Only stock I have that’s currently +130% because I’m in at $4.80. I also have some ELTP but not enough to brag about.
Gained 3k with a $600 rddt call but lost 4k on CRMD stocks. not a bad day!
CRMD 
CRMD 
CRMD - they make a medication for dialysis catheters to prevent infection, i bought before the FDA approval so got a nice bump after that happened, probably has some more upside over the next couple of years barring any bad side effects.
CRMD. A little over 10M shares short and they are massively underwater right now. Check for yourself.
No debt, in this case, just means creditors don't find this company credit worthy. They've been printing $40\~50 millions of stocks a year since 2020 to prop the company up. In purely financial terms, this company is in terrible shape. Spiraling negative operating cashflows. Revenue dropping every year into 0. [https://finance.yahoo.com/quote/CRMD/financials/](https://finance.yahoo.com/quote/CRMD/financials/) These bio/pharma small caps can always pop on the next "break through" news. Feel free to speculate on those. But if you think their financials look good, you are dead wrong.
CRMD, going to 10 on earnings next month. Risky play but if you’re not gambling your account on biotech penny stocks what are you even doing 
Still holding my CRMD while we slowly cook the shorts. Do your own DD but get in while you still can.
Psssst……we’re squeezing the shorts at CRMD. Getting ready for the next leg up. Pass it on.
I almost bought CRMD a month ago, just checked back and it's up 88% 
I have lunr calls for 9/20 OI was strong at the strike price I could afford. Was ITM now its down a little. Got jammed up in 9/20 6$ CRMD calls waiting to see what that does. Got into SOFI calls too then that went down. Finally went in on UVIX. Just need something to pop lol it’s my gambling account so if I lose it it’s fine. But would be nice to be right. Made some money then lost a big chunk playing NVDA calls :(
It was from one if those email "three stocks Yada Yada" that I first learned about CRMD, granted it's been about a year, but it just jumped 30% on earnings today when they showed they didn't gk out of business bringing their medicine to market